Advancedadvanced biology

DNA Damage Response: Sensing and Repairing Breaks

Learning objectives

  • Catalog major lesion types and the sensors that detect them (MRN, RPA-ATRIP).
  • Trace signal amplification from ATM/ATR through Chk1/Chk2 to p53 and Cdc25.
  • Explain the choice between homologous recombination and non-homologous end joining.
  • Evaluate BRCA1/2 function and the synthetic-lethal logic of PARP inhibitors.
  • Describe how damage severity is converted into arrest, senescence, or apoptosis.

The damage landscape and its sensors

DNA suffers tens of thousands of lesions per cell per day: oxidative base damage, single-strand breaks, bulky adducts, mismatches, and the most dangerous -- double-strand breaks (DSBs), where both backbones sever. Each lesion type has dedicated sensors. The MRN complex (MRE11-RAD50-NBS1) is the DSB sensor: it binds broken ends, tethers them, and recruits and activates the ATM kinase -- MRE11's nuclease activity also begins resecting ends for repair. Single-stranded DNA, the universal intermediate of stalled replication and resection, is coated by RPA, which recruits ATR via its partner ATRIP; the 9-1-1 clamp and TOPBP1 then fully activate ATR. Base damage and mismatches are detected by their own glycosylases and MutS homologs, feeding into overlapping signaling. The sensor architecture reveals a principle: the cell does not detect 'damage' abstractly but recognizes specific abnormal DNA structures -- a free end, an RPA-coated stretch, a helix distortion -- and each structure summons its own kinase.

Amplifying the alarm: ATM/ATR cascades

A single DSB must halt the entire cell -- amplification is essential. Activated ATM phosphorylates histone H2AX over megabase-scale chromatin domains surrounding the break, creating gamma-H2AX; the scaffold protein MDC1 binds gamma-H2AX and recruits more MRN-ATM, a positive feedback loop that spreads the signal outward from the lesion like a stain. ATM then phosphorylates the effector kinases Chk2 (and ATR phosphorylates Chk1), which diffuse through the nucleus inactivating Cdc25 phosphatases -- immediately freezing cell-cycle progression -- while ATM/ATR also phosphorylate p53 and its regulator MDM2, stabilizing p53 to launch the transcriptional program. Dozens of substrates are modified: repair factors are recruited and activated, transcription near the break is silenced, and chromatin is remodeled for access. The gamma-H2AX focus visible by immunofluorescence -- one bright dot per DSB -- is this amplification made visible, and counting foci is how researchers quantify breaks. What began as a broken backbone becomes a cell-wide state change within minutes.

Choosing the repair: HR versus NHEJ

A DSB faces two main fates. Non-homologous end joining (NHEJ) -- initiated when the Ku70/Ku80 ring threads onto the broken ends -- simply ligates them, fast and available throughout the cell cycle but error-prone: ends are often trimmed or filled, leaving small indels. Homologous recombination (HR) -- initiated by extensive 5'-to-3' end resection -- uses the sister chromatid as a template for error-free repair, but is restricted to S and G2 when a sister exists. The choice is regulated by a molecular tug-of-war: 53BP1 protects ends and promotes NHEJ, while BRCA1 counteracts 53BP1 to permit resection and HR; CDK activity in S/G2 favors BRCA1, biasing toward HR when a template is available. Pathway choice matters enormously: NHEJ's speed suits G1, but its mutagenicity at resected ends can cause translocations -- the initiating lesions of many cancers. Specialized variants (alternative end joining, single-strand annealing) handle cases where the main pathways fail or are unavailable, usually with greater mutagenicity.

BRCA1/2 and synthetic lethality

BRCA1 and BRCA2 are HR mediators, not sensors: BRCA1 promotes end resection and counteracts 53BP1, while BRCA2 loads the RAD51 recombinase onto resected single-stranded DNA, forming the nucleoprotein filament that invades the sister chromatid. Germline mutations in either cause hereditary breast and ovarian cancer -- not because HR loss directly transforms cells, but because error-prone backup repair generates the mutations that do. The therapeutic insight was synthetic lethality: BRCA-deficient cells cannot perform HR, so they depend on PARP-dependent backup pathways to survive endogenous damage; PARP inhibitors trap PARP on DNA, creating lesions that require HR -- killing BRCA-mutant cancer cells while sparing normal cells that retain one functional BRCA allele. Olaparib and its successors turned a DNA-repair defect into a drug target and validated a general strategy: find what the tumor lost, then block what it now depends on. Resistance arises through secondary BRCA reversion mutations or loss of 53BP1 -- the pathway's logic predicting, again, the escape.

From signal to fate: arrest, senescence, or death

The DDR does not only repair -- it decides the cell's future. Moderate damage triggers transient arrest via p21-mediated CDK inhibition, buying time for repair; successful repair extinguishes the signal (phosphatases remove gamma-H2AX, p53 decays) and the cycle resumes. Persistent signaling drives senescence -- a permanent, metabolically active arrest enforced by p16 and p21, with the senescence-associated secretory phenotype alerting the immune system; senescence is tumor-suppressive but its accumulation drives aging phenotypes. Severe or irreparable damage flips p53's program from arrest genes to pro-apoptotic genes (Puma, Noxa, Bax), executing the cell. The dose-response is thus qualitative, not merely quantitative: the same p53 protein, differentially modified and partnered, transcribes different gene sets at different damage levels. Chemotherapy and radiotherapy exploit this entire architecture -- inflicting damage that overwhelms repair in rapidly dividing, checkpoint-defective cancer cells -- which is why DDR inhibitors are among the most promising chemosensitizers in oncology.

Structure, not damage, is sensed

MRN recognizes free DNA ends; RPA-ATRIP recognizes coated single-stranded DNA. The DDR is triggered by abnormal DNA structures, each summoning its own kinase cascade -- ATM for breaks, ATR for stalled forks.

Key points

  • Sensors recognize abnormal structures: MRN binds DSB ends and activates ATM; RPA-coated ssDNA recruits ATR via ATRIP.
  • ATM spreads gamma-H2AX over megabase domains in a positive feedback loop; Chk1/Chk2 freeze the cycle via Cdc25; p53 launches the transcriptional program.
  • NHEJ (Ku-initiated, fast, error-prone) dominates in G1; HR (resection-initiated, template-based, accurate) operates in S/G2; 53BP1 vs BRCA1 adjudicates.
  • BRCA1 promotes resection, BRCA2 loads RAD51; PARP inhibitors are synthetic-lethal in BRCA-deficient tumors.
  • Damage severity is converted into transient arrest, senescence, or apoptosis by differentially programmed p53 -- the logic chemotherapy exploits.

Common misconceptions

✗ Myth: The cell detects DNA damage directly.

✓ Truth: Sensors recognize abnormal DNA structures -- free ends, RPA-coated ssDNA, helix distortions -- not 'damage' as an abstract property. Structure summons the kinase.

✗ Myth: Homologous recombination is always the better repair.

✓ Truth: HR is accurate but requires a sister chromatid (S/G2) and is slow; NHEJ's speed makes it the right choice in G1 despite its mutagenicity.

✗ Myth: PARP inhibitors work by blocking DNA repair generally.

✓ Truth: They trap PARP on DNA creating HR-dependent lesions -- selectively lethal only in HR-deficient (e.g., BRCA-mutant) cells. Normal cells are spared.

Frequently asked questions

What does the MRN complex do?

It senses double-strand breaks: binding and tethering broken ends, recruiting and activating ATM, and beginning end resection with MRE11's nuclease activity.

What is gamma-H2AX?

Histone H2AX phosphorylated by ATM over megabase domains around a break. It recruits MDC1 and more ATM in a feedback loop -- visible as one focus per DSB, the standard break assay.

How is HR vs NHEJ chosen?

53BP1 protects ends for NHEJ; BRCA1 counteracts it to allow resection for HR. CDK activity in S/G2 favors BRCA1, restricting accurate HR to when a sister chromatid exists.

Why are PARP inhibitors synthetic-lethal with BRCA mutations?

PARP trapping creates lesions requiring homologous recombination. BRCA-deficient cancer cells cannot perform HR and die; normal cells with functional BRCA survive.

How does the cell choose between arrest and apoptosis?

Damage level and persistence differentially program p53: moderate damage induces p21-mediated arrest; severe irreparable damage switches p53 to pro-apoptotic genes like Puma and Noxa.